$0.01
(Market cap
$3,519 Mln
Revenue (TTM)
$6,163 Mln
P/E Ratio
14.4
P/B Ratio
3.9
Div. Yield
0.6 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$100 Mln
-
ROE
0.3 %
-
ROCE
2 %
-
Industry P/E
30.75
-
EV/EBITDA
7.9
-
Debt to Equity
9.5
-
Book Value
$--
-
EPS
$0.9
-
Face value
--
-
Shares outstanding
262,600,862
7 Years Aggregate
CFO
$16,175.00 Mln
EBITDA
$16,741.00 Mln
Net Profit
$12,623.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Organon & Co. (OGN)
| 86.9 | 0.4 | 104.3 | 40.2 | -12.5 | -14.3 | -- |
|
BSE Sensex*
| -12.0 | -3.7 | -4.0 | -9.6 | 6.0 | 7.5 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Organon & Co. (OGN)
| -51.9 | 3.4 | -48.4 | -8.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Organon & Co. (OGN)
|
13.4 | 3,518.9 | 6,163.0 | 246.0 | 15.7 | 27.2 | 14.4 | 3.9 |
| 14.7 | 4,386.6 | 3,045.9 | 122.4 | 13.8 | -- | 37.2 | 105.4 | |
| 41.0 | 5,252.7 | 1,105.3 | 133.3 | 15.9 | 32.7 | 38.3 | 12.7 | |
| 245.6 | 11,955.1 | 708.2 | -188.3 | -25.6 | -293.5 | -- | 218.2 | |
| 67.7 | 13,242.2 | 580.0 | -725.9 | -105.2 | -- | -- | 123.7 | |
| 77.5 | 7,795.9 | 769.1 | 47.9 | 5.4 | 7.5 | 207.5 | 12.2 | |
| 24.5 | 11,876.9 | 4,893.0 | -242.0 | -1.5 | -3.7 | -- | 1.8 | |
| 7.3 | 5,199.6 | 7,447.6 | 415.6 | 16.2 | 6.6 | 10.8 | 0.8 | |
| 243.3 | 4,749.7 | 274.5 | 153.6 | 76.6 | 15.8 | 30.9 | 4.8 | |
| 64.0 | 5,500.2 | 288.1 | 22.3 | 17.5 | 34.1 | 363.8 | 51.2 |
Shareholding Pattern
View DetailsAbout Organon & Co. (OGN)
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and... internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey. Read more
-
CEO & Director
Mr. Kevin Ali
-
Executive VP & CFO
Mr. Matthew M. Walsh C.F.A.
-
Headquarters
Jersey City, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Organon & Co. (OGN)
What is the current share price of Organon & Co (OGN) Today?
The share price of Organon & Co (OGN) is $13.40 (NYSE) as of 09-Jun-2026 16:20 EDT. Organon & Co (OGN) has given a return of -12.51% in the last 3 years.
What is the current PB & PE ratio of Organon & Co (OGN)?
The P/E ratio of Organon & Co (OGN) is 14.41 times as on 05-Jun-2026, a 53 discount to its peers’ median range of 30.75 times.
The P/B ratio of Organon & Co (OGN) is 3.89 times as on 05-Jun-2026, a 30 discount to its peers’ median range of 5.54 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
9.98
|
2.48
|
|
2024
|
4.49
|
8.21
|
|
2023
|
3.62
|
-52.86
|
|
2022
|
7.78
|
-8.00
|
|
2021
|
5.74
|
-5.14
|
What is the 52 Week High and Low of Organon & Co (OGN)?
The 52-week high and low of Organon & Co (OGN) are Rs 13.48 and Rs 5.69 as of 10-Jun-2026.
What is the market cap of Organon & Co (OGN)?
Organon & Co (OGN) has a market capitalisation of $ 3,519 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Organon & Co (OGN)?
Before investing in Organon & Co (OGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.